obesity drug news today glp-1 september 2025 Alarming rise in weight loss overdoses Patients taking an experimental oral

Plaintiffs in the litigation report experiencing these specific digestive system complications: Gastroparesis (stomach paralysis): The most common injury alleged in lawsuits, this condition involves partial or complete paralysis of stomach muscles that prevents proper digestion and can persist even after discontinuing medication Ileus (intestinal blockage): Added to FDA warning labels in September 2023 after post-marketing reports, this condition stops intestinal movement and can lead to life-threatening complications including infection and tissue death Intestinal obstruction and pseudo-obstruction: Physical or functional blockages requiring emergency hospitalization and often surgical intervention to prevent bowel perforation Chronic severe symptoms: Persistent vomiting, uncontrollable nausea, dangerous dehydration requiring IV fluids, and electrolyte imbalances necessitating repeated emergency department visits The FDAs decision to update warning labels demonstrates growing concern about these complications

Your follow-up appointment, typically 4-6 weeks after starting, is just as important as the initial visit

However, the GLP-1 medications have some pretty intense side effects

A conservative approach is to order smaller quantities initially, test them, and scale up only after confirming quality through independent verification

If your plan includes coverage for weight management medications, we will continue to leverage aggressive formulary and UM strategies to help ensure cost-effective, clinically appropriate coverage consistent with Food and Drug Administration (FDA)-approved labeling and clinical compendia

Diabetes Obes Metab 14:514 Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, The PROactive Investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macro vascular events): a randomised controlled trial